Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 10180Neoplasms 7807Carcinoma, Non-Small-Cell Lung 5756Prostatic Neoplasms 5024Colorectal Neoplasms 4603Lung Neoplasms 3723Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3082Multiple Myeloma 3081Pancreatic Neoplasms 2843Melanoma 2651Ovarian Neoplasms 2573Lymphoma 2570Carcinoma, Hepatocellular 2479Stomach Neoplasms 2329Recurrence 2229Head and Neck Neoplasms 2102Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2057Leukemia 2013Brain Neoplasms 1902Glioblastoma 1795Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1719Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Metastatic Gastric Adenocarcinoma × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT02314117 2021-08-26

RAINFALL

Eli Lilly and Company

Phase 3 Completed
645 enrolled 22 charts
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡